tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Teladoc (TDOC) and Anavex Life Sciences (AVXL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Conmed (CNMDResearch Report), Teladoc (TDOCResearch Report) and Anavex Life Sciences (AVXLResearch Report).

Conmed (CNMD)

In a report released today, Michael Matson from Needham reiterated a Buy rating on Conmed, with a price target of $123.00. The company’s shares closed last Monday at $97.57, close to its 52-week low of $87.24.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 3.8% and a 48.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Conmed has an analyst consensus of Strong Buy, with a price target consensus of $120.25, a 25.1% upside from current levels. In a report issued on July 28, Piper Sandler also maintained a Buy rating on the stock with a $118.00 price target.

See today’s best-performing stocks on TipRanks >>

Teladoc (TDOC)

In a report released today, Dev Weerasuriya from Berenberg Bank downgraded Teladoc to Hold, with a price target of $35.00. The company’s shares closed last Monday at $36.81, close to its 52-week low of $27.38.

According to TipRanks.com, Weerasuriya is a 2-star analyst with an average return of 0.2% and a 47.4% success rate. Weerasuriya covers the Technology sector, focusing on stocks such as Health Catalyst, Omnicell, and Accolade.

Currently, the analyst consensus on Teladoc is a Hold with an average price target of $38.63, implying a 5.8% upside from current levels. In a report issued on July 28, Goldman Sachs also downgraded the stock to Hold with a $36.00 price target.

Anavex Life Sciences (AVXL)

In a report released today, Caroline Palomeque from Berenberg Bank maintained a Buy rating on Anavex Life Sciences, with a price target of $40.00. The company’s shares closed last Monday at $9.88, close to its 52-week low of $7.13.

According to TipRanks.com, Palomeque is ranked #7775 out of 7992 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anavex Life Sciences with a $35.20 average price target, representing a 227.1% upside. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $40.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CNMD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More